Literature DB >> 35592436

Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats.

Bethany Crouse1,2, Mariah M Wu1,2, Valeria Gradinati1, Andrew J Kassick3, Daihyun Song1, Rajwana Jahan4, Saadyah Averick3, Scott Runyon4, Sandra D Comer5, Marco Pravetoni1,6,7.   

Abstract

Drug-related fatal overdoses have significantly increased in the past decade due to the widespread availability of illicit fentanyl and other potent synthetic opioids such as carfentanil. Deliberate or accidental consumption or exposure to carfentanil, fentanyl, and their mixture induces respiratory depression and bradycardia that can be difficult to reverse with the opioid receptor antagonist naloxone. Vaccines offer a promising strategy to reduce the incidence of fatalities associated with fentanyl-related substances, as well as treatment for opioid use disorder (OUD). This study reports monovalent and bivalent vaccination strategies that elicit polyclonal antibody responses effective in protecting against the pharmacological actions of carfentanil, fentanyl, or carfentanil/fentanyl mixtures. Rats were prophylactically immunized with individual conjugate vaccines containing either carfentanil- or fentanyl-based haptens, or their combination in bivalent vaccine formulations, and then challenged with carfentanil, fentanyl, or their mixture. First, these studies identified a lead vaccine protective against carfentanil-induced antinociception, respiratory depression, and bradycardia. Then, efficacy against both carfentanil and fentanyl was achieved through bivalent vaccination strategies that combined lead anti-carfentanil and anti-fentanyl vaccines via either heterologous prime/boost or co-administration immunization regimens. These preclinical data support the development of vaccines as a viable strategy to prevent toxicity from exposure to excessive doses of carfentanil, fentanyl, or their mixtures.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35592436      PMCID: PMC9112413          DOI: 10.1021/acsptsci.1c00260

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  44 in total

1.  Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats.

Authors:  S D Satoskar; D E Keyler; M G LeSage; D E Raphael; C A Ross; P R Pentel
Journal:  Int Immunopharmacol       Date:  2003-07       Impact factor: 4.932

2.  Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

Authors:  Sabina H L de Villiers; Katherine E Cornish; Andrew J Troska; Marco Pravetoni; Paul R Pentel
Journal:  Vaccine       Date:  2013-10-29       Impact factor: 3.641

3.  Vaccine blunts fentanyl potency in male rhesus monkeys.

Authors:  Rebekah D Tenney; Steven Blake; Paul T Bremer; Bin Zhou; Candy S Hwang; Justin L Poklis; Kim D Janda; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-07-29       Impact factor: 5.250

4.  The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Authors:  Megan Laudenbach; Federico Baruffaldi; Jeffrey S Vervacke; Mark D Distefano; Philip J Titcombe; Daniel L Mueller; Noah J Tubo; Thomas S Griffith; Marco Pravetoni
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

Review 5.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

6.  Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation.

Authors:  F Baruffaldi; M D Raleigh; S J King; M J Roslawski; A K Birnbaum; C Hassler; F I Carroll; S P Runyon; S Winston; P R Pentel; M Pravetoni
Journal:  Mol Pharm       Date:  2019-05-14       Impact factor: 4.939

7.  Efficacious Vaccine against Heroin Contaminated with Fentanyl.

Authors:  Candy S Hwang; Lauren C Smith; Yoshihiro Natori; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2018-03-23       Impact factor: 4.418

Review 8.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Authors:  Randy Torralva; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

9.  Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.

Authors:  M D Raleigh; S J King; F Baruffaldi; A Saykao; F A Hamid; S Winston; M G LeSage; P R Pentel; M Pravetoni
Journal:  Neuropharmacology       Date:  2021-06-11       Impact factor: 5.273

10.  Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose.

Authors:  Joseph V Pergolizzi; Lynn R Webster; Eugene Vortsman; Jo Ann LeQuang; Robert B Raffa
Journal:  J Clin Pharm Ther       Date:  2021-07-08       Impact factor: 2.512

View more
  1 in total

1.  Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats.

Authors:  Carly Baehr; Christine Robinson; Andrew Kassick; Rajwana Jahan; Valeria Gradinati; Saadyah E Averick; Scott P Runyon; Marco Pravetoni
Journal:  ACS Omega       Date:  2022-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.